Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$9.19 USD
-0.20 (-2.13%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.21 +0.02 (0.22%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Earnings News For ADVM
-
Adverum Biotechnologies: Q4 Earnings Snapshot
-
Adverum Biotechnologies: Q4 Earnings Snapshot
-
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
-
Adverum Biotechnologies: Q3 Earnings Snapshot
-
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
-
Adverum Biotechnologies: Q2 Earnings Snapshot
-
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
-
Adverum Biotechnologies: Q1 Earnings Snapshot
-
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
-
Adverum Biotechnologies: Q4 Earnings Snapshot
-
Adverum Biotechnologies: Q4 Earnings Snapshot
-
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
-
Adverum Biotechnologies: Q3 Earnings Snapshot
-
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
-
Adverum Biotechnologies: Q2 Earnings Snapshot
-
Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
-
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue Estimates
-
Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates
-
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates
-
Analysts Estimate Adverum Biotechnologies (ADVM) to Report a Decline in Earnings: What to Look Out for
-
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates
-
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates
-
Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates
-
Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline
-
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates